The evaluation of potential toxicological effects of all pharmaceuticals
is required prior to product registration. The safety evaluation of these products
is performed in mammalian systems, for which extensive background data can be
of great value in the evaluation of responses observed in the studies. Huntingdon
Life Sciences, with over fifty years experience in this work is ideally placed
to assist you with this testing.
We have the capacity and a wide variety of the necessary skills,
enabling us to design and conduct all study types in accordance with the requirements
of the product under test. For example, all the common dosing routes, such as
dermal, inhalation, intravenous injection and oral are available, as well as
some other specialist routes such as vascular infusion and intrathecal. All
areas of regulatory toxicology enabling a Phase II clinical trial can be covered:
- Rodent and non-rodent repeat-dose studies (medium-term)
- Clinical pathology (with the capability to perform none-routine assays,
e.g. quantification of various cytokines or hormones)
- Immunotoxicology: Flow Cytometry, Natural Killer Cell Assay and Antibody
Plaque-Forming Cell Assay can be incorporated into study designs
- Toxicokinetic evaluation with a pro-active approach to preventing contamination
of control samples
- Electrocardiography and blood pressure measurement in large mammals
- Reproductive toxicology studies covering
pregnancy and fertility
Together with our extensive support departments, we provide
the full comprehensive package of tests required for registration and market
authorisation, which ultimately helps speed your product to market.
|
